JP2016533775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533775A5 JP2016533775A5 JP2016518431A JP2016518431A JP2016533775A5 JP 2016533775 A5 JP2016533775 A5 JP 2016533775A5 JP 2016518431 A JP2016518431 A JP 2016518431A JP 2016518431 A JP2016518431 A JP 2016518431A JP 2016533775 A5 JP2016533775 A5 JP 2016533775A5
- Authority
- JP
- Japan
- Prior art keywords
- paste
- salt
- weight
- paste composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001661 Chitosan Polymers 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 24
- 229910019142 PO4 Inorganic materials 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 13
- 239000010452 phosphate Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 206010052428 Wound Diseases 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 231100000065 noncytotoxic Toxicity 0.000 claims description 2
- 230000002020 noncytotoxic effect Effects 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims 1
- 150000003893 lactate salts Chemical class 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 229920002807 Thiomer Polymers 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- -1 glutamate salts Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/061,993 US9192692B2 (en) | 2013-10-24 | 2013-10-24 | Chitosan stenting paste |
| US14/061,993 | 2013-10-24 | ||
| US14/319,901 US9192574B2 (en) | 2013-10-24 | 2014-06-30 | Chitosan paste wound dressing |
| US14/319,901 | 2014-06-30 | ||
| PCT/US2014/062041 WO2015061612A1 (en) | 2013-10-24 | 2014-10-23 | Chitosan paste wound dressing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533775A JP2016533775A (ja) | 2016-11-04 |
| JP2016533775A5 true JP2016533775A5 (enExample) | 2018-09-20 |
| JP6491647B2 JP6491647B2 (ja) | 2019-03-27 |
Family
ID=51862592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518431A Active JP6491647B2 (ja) | 2013-10-24 | 2014-10-23 | キトサンペースト創傷手当て材 |
| JP2016522114A Active JP6397491B2 (ja) | 2013-10-24 | 2014-10-23 | キトサンステント材ペースト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522114A Active JP6397491B2 (ja) | 2013-10-24 | 2014-10-23 | キトサンステント材ペースト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9192574B2 (enExample) |
| EP (2) | EP3060266B1 (enExample) |
| JP (2) | JP6491647B2 (enExample) |
| AU (2) | AU2014340012B2 (enExample) |
| CA (2) | CA2927357A1 (enExample) |
| ES (2) | ES2755137T3 (enExample) |
| WO (2) | WO2015061606A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8932560B2 (en) | 2007-09-04 | 2015-01-13 | University of Maryland, College Parke | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells |
| US8668899B2 (en) | 2009-11-13 | 2014-03-11 | University Of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
| US9616088B2 (en) | 2013-03-13 | 2017-04-11 | Gel-E, Inc. | Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells |
| EP3569262A1 (en) | 2013-03-14 | 2019-11-20 | Tricol Biomedical, Inc. | Biocompatible and bioabsorbable derivatized chitosan compositions |
| WO2017032897A1 (en) | 2015-08-27 | 2017-03-02 | Alimentary Health Limited | Use of bifidobacterium longum and an exopolysaccharide produced thereby |
| US10576099B2 (en) | 2016-10-21 | 2020-03-03 | Covidien Lp | Injectable scaffold for treatment of intracranial aneurysms and related technology |
| EP3532111B1 (en) * | 2016-10-26 | 2021-01-20 | Biointelligence Systems S.L. | Bone bioactive composition and uses thereof |
| GB2595144B (en) * | 2019-02-08 | 2023-07-26 | Chitogel Ltd | Surgical hydrogel |
| CN114630627A (zh) | 2019-11-04 | 2022-06-14 | 柯惠有限合伙公司 | 用于治疗颅内动脉瘤的装置、系统和方法 |
| US12364793B2 (en) | 2021-03-16 | 2025-07-22 | Covidien Lp | Injectable biopolymer compositions and associated systems and methods |
| EP4084580A1 (en) * | 2021-04-30 | 2022-11-02 | Koninklijke Philips N.V. | A light output system and design method |
| KR102852787B1 (ko) * | 2021-12-28 | 2025-08-28 | 단국대학교 천안캠퍼스 산학협력단 | 신규한 화합물을 포함하는 생리 식염수 |
| EP4572811A1 (en) * | 2022-11-10 | 2025-06-25 | Hemostasis LLC | Dressing formulations |
| CN116059430B (zh) * | 2022-12-16 | 2025-09-23 | 无锡学院 | 一种可降解伤口敷料及其制备方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394373A (en) | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
| US4532134A (en) | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
| US4452785A (en) | 1982-11-08 | 1984-06-05 | Malette William Graham | Method for the therapeutic occlusion |
| CA1202904A (en) | 1983-11-21 | 1986-04-08 | Brian G. Sparkes | Chitosan based wound dressing materials |
| US4659700A (en) | 1984-03-02 | 1987-04-21 | Johnson & Johnson Products, Inc. | Chitosan-glycerol-water gel |
| JPH0735281B2 (ja) | 1988-02-16 | 1995-04-19 | 学校法人松本歯科大学 | 硬化性組成物 |
| US4956350A (en) | 1988-08-18 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Wound filling compositions |
| US5124151A (en) | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
| US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| US5871985A (en) | 1992-09-28 | 1999-02-16 | Brown University Research Foundation | Particulate non cross-linked chitosan core matrices for encapsulated cells |
| GB2276819B (en) | 1993-03-23 | 1996-12-11 | Johnson & Johnson Medical | Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol |
| US5531716A (en) | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
| US5622834A (en) | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| SE9402531L (sv) | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
| GB9421969D0 (en) | 1994-10-28 | 1994-12-21 | Innovative Tech Ltd | Wound treatment composition |
| USRE38431E1 (en) | 1995-12-01 | 2004-02-17 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
| WO1998051709A1 (en) | 1997-05-13 | 1998-11-19 | Young Keun Hong | Aqueous cellulose solution and rayon fiber produced from the same |
| CA2212300A1 (en) | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
| US6458375B1 (en) | 1998-02-27 | 2002-10-01 | Musculoskeletal Transplant Foundation | Malleable paste with allograft bone reinforcement for filling bone defects |
| ATE243049T1 (de) | 1999-12-09 | 2003-07-15 | Biosyntech Canada Inc | Mineral-polymer hybrid-zusammensetzung |
| JP5089006B2 (ja) | 2000-06-29 | 2012-12-05 | ピラマル ヘルスケア （カナダ） リミテッド | 軟骨および他の組織の修復および再生のための組成物および方法 |
| EP1190702A1 (en) | 2000-09-22 | 2002-03-27 | Ciba SC Holding AG | Chitosan emulsion formulation |
| CA2429165A1 (en) | 2000-11-15 | 2002-05-23 | Bio Syntech Canada Inc. | Filler composition for soft tissue augmentation and reconstructive surgery |
| US20020058704A1 (en) | 2000-11-15 | 2002-05-16 | Kimberly-Clark Worldwide, Inc. | Multicomponent compositions containing chitosan and methods of preparing same |
| ATA13842001A (de) | 2001-08-31 | 2002-10-15 | Mucobiomer Biotechnologische F | Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung |
| ES2357889T3 (es) | 2001-11-15 | 2011-05-03 | Piramal Healthcare (Canada) Limited | Composición y método para reticular o modificar homogéneamente quitosano en condiciones neutras. |
| JP3947391B2 (ja) | 2001-11-28 | 2007-07-18 | 独立行政法人 日本原子力研究開発機構 | 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法 |
| FR2836044A1 (fr) | 2002-02-15 | 2003-08-22 | Octaris | Composition pour la reparation et la cicatrisation cutanee comprenant exclusivement un vrai hydrogel physique de chitosane |
| US20060127873A1 (en) | 2002-07-16 | 2006-06-15 | Caroline Hoemann | Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
| WO2004033502A1 (ja) | 2002-10-08 | 2004-04-22 | Ricom Corporation | キトサン含有多糖、その製造方法及び用途 |
| JP2006347883A (ja) * | 2003-09-08 | 2006-12-28 | Neetec:Kk | 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物 |
| US7968122B2 (en) | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
| US8124120B2 (en) | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
| GB0329918D0 (en) | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| GB0403938D0 (en) | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
| JP2005281654A (ja) * | 2004-03-31 | 2005-10-13 | Rikogaku Shinkokai | 温度応答性組成物およびそのヒドロゲル |
| ITRM20040539A1 (it) | 2004-11-02 | 2005-02-02 | Mavi Sud S R L | Preparati a base di chitina o suoi derivati per uso cosmetico o medico. |
| WO2006067626A2 (en) | 2004-12-20 | 2006-06-29 | Carbgraft Ab | Chitosan compositions |
| US20060287278A1 (en) | 2005-06-21 | 2006-12-21 | Zhenze Hu | Method for improving water solubility of chitosan |
| CA2628244A1 (en) | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
| CA2636050C (en) | 2006-01-25 | 2015-03-31 | University Of Virginia Patent Foundation | Methods for regulating gelation of polysaccharide solutions and uses thereof |
| CA2643322C (en) | 2006-02-24 | 2015-07-21 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
| US20070264296A1 (en) | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
| US7959943B2 (en) | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
| US7976873B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
| WO2008127287A2 (en) | 2006-10-11 | 2008-10-23 | Biolife, L.L.C. | Materials and methods for wound treatment |
| US8153612B2 (en) | 2006-12-11 | 2012-04-10 | Chi2Gel Ltd. | Injectable chitosan mixtures forming hydrogels |
| EP2155274A4 (en) | 2007-06-13 | 2012-11-28 | Fmc Corp | IMPLANTABLE DEVICES BASED ON DEGRADABLE BIOPOLYMERIC FIBERS |
| WO2009056602A1 (en) | 2007-10-30 | 2009-05-07 | Viscogel Ab | Chitosan composition |
| WO2009114535A2 (en) | 2008-03-10 | 2009-09-17 | Marfly 2, Lp | Bone paste composition |
| EP2296637B1 (en) | 2008-04-24 | 2014-04-02 | Medtronic, Inc | Chitosan-containing protective composition |
| CA2721985C (en) | 2008-04-24 | 2016-06-21 | Medtronic, Inc. | Thiolated chitosan gel for treating mucosal tissue |
| CA2722155C (en) | 2008-04-24 | 2019-07-30 | Medtronic, Inc. | Cold ionizing radiation sterilization |
| RU2513142C2 (ru) | 2008-06-12 | 2014-04-20 | Медтроник Ксомед Инк. | Способ лечения хронических ран |
| WO2010033943A1 (en) | 2008-09-19 | 2010-03-25 | The Trustees Of The University Of Pennsylvania | Biodegradable stent |
| EP2473042B1 (en) | 2009-09-02 | 2017-08-02 | Synedgen, Inc. | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| EP2501392B1 (en) | 2009-11-19 | 2018-09-19 | Ortho Regenerative Technologies Inc. | Soluble physiological chitosan formulations combined with platelet-rich plasma (prp) for tissue repair |
| WO2011060545A1 (en) | 2009-11-19 | 2011-05-26 | Corporation De L'ecole Polytechnique De Montreal | Specific blood:chitosan mixing ratios producing a viscous paste-like implant with good handling properties for tissue repair |
| CN102469782A (zh) | 2010-06-18 | 2012-05-23 | 哈洛资源公司 | 包含壳聚糖的固态共混物的制剂及方法 |
| US8506972B2 (en) | 2010-08-27 | 2013-08-13 | Oligo Medic Inc | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions |
-
2014
- 2014-06-30 US US14/319,901 patent/US9192574B2/en active Active
- 2014-10-23 AU AU2014340012A patent/AU2014340012B2/en active Active
- 2014-10-23 WO PCT/US2014/062029 patent/WO2015061606A1/en not_active Ceased
- 2014-10-23 JP JP2016518431A patent/JP6491647B2/ja active Active
- 2014-10-23 ES ES14793731T patent/ES2755137T3/es active Active
- 2014-10-23 ES ES14793730T patent/ES2765348T3/es active Active
- 2014-10-23 JP JP2016522114A patent/JP6397491B2/ja active Active
- 2014-10-23 WO PCT/US2014/062041 patent/WO2015061612A1/en not_active Ceased
- 2014-10-23 CA CA2927357A patent/CA2927357A1/en not_active Abandoned
- 2014-10-23 CA CA2926401A patent/CA2926401C/en not_active Expired - Fee Related
- 2014-10-23 EP EP14793731.2A patent/EP3060266B1/en active Active
- 2014-10-23 EP EP14793730.4A patent/EP3060265B1/en active Active
- 2014-10-23 AU AU2014340006A patent/AU2014340006B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533775A5 (enExample) | ||
| Frigaard et al. | The potential of chitosan in nanomedicine: An overview of the cytotoxicity of chitosan based nanoparticles | |
| Bhat et al. | Polysaccharide-based nanomedicines targeting lung cancer | |
| Osmałek et al. | Recent advances in polymer-based vaginal drug delivery systems | |
| Pistone et al. | Formulation of polysaccharide-based nanoparticles for local administration into the oral cavity | |
| Chandel et al. | Self-assembly of partially alkylated dextran-graft-poly [(2-dimethylamino) ethyl methacrylate] copolymer facilitating hydrophobic/hydrophilic drug delivery and improving conetwork hydrogel properties | |
| JP6491647B2 (ja) | キトサンペースト創傷手当て材 | |
| Vecchies et al. | Complex coacervates between a lactose-modified chitosan and hyaluronic acid as radical-scavenging drug carriers | |
| KR101783448B1 (ko) | 표면 처리된 나노섬유를 포함하는 하이드로젤 및 이의 제조방법 | |
| Muhsin et al. | Effects of chemical conjugation of L-leucine to chitosan on dispersibility and controlled release of drug from a nanoparticulate dry powder inhaler formulation | |
| AU2014340006A1 (en) | Chitosan stenting paste | |
| AU2014340012A1 (en) | Chitosan paste wound dressing | |
| HRP20220537T1 (hr) | Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol | |
| Song et al. | Effect of net surface charge on physical properties of the cellulose nanoparticles and their efficacy for oral protein delivery | |
| US20190125896A1 (en) | Anti-infective compositions comprising phytoglycogen nanoparticles | |
| US20200101103A1 (en) | Reinforcement of mucus barrier properties | |
| Bosio et al. | Tailoring doxorubicin sustainable release from biopolymeric smart matrix using congo red as molecular helper | |
| Depani et al. | Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU) | |
| JP2017206502A (ja) | 関節内補充療法のためのポリマー溶液 | |
| Tekale et al. | Polysaccharide-based Biomaterials: Overview | |
| CN106963958A (zh) | 多糖水溶液的灭菌方法及无菌的多糖水溶液 | |
| Khushbu | Carboxymethyl tamarind kernel gum based controlled drug delivery excipients: a review | |
| Cadinoiu et al. | Biocompatible injectable polysaccharide materials for drug delivery | |
| KR20220075345A (ko) | 지속 방출 하이드로겔 조성물 | |
| TW201536350A (zh) | 溫敏型可注射式青光眼藥物載體凝膠及其製備方法 |